Chronic graft-versus-host disease (GVHD) commonly occurs after allogeneic hematopoietic
cell transplantation (HCT) despite standard prophylactic immune suppression. Intensified …

Preventing chronic graft-versus-host disease (GVHD) remains challenging because the
unique cellular and molecular pathways that incite chronic GVHD are poorly understood …

journal homepage: www. tctjournal. org standardize or revise clinical research tools but
rather to stimulate the field by identifying basic and clinical research directions that may lead …

Recognition of the earliest signs and symptoms of chronic graft-versus-host disease (GVHD)
that lead to severe manifestations remains a challenge. The standardization provided by the …

Positive results from recent clinical trials have significantly expanded current therapeutic
options for patients with chronic graft-versus-host disease (GVHD). However, new insights …

Abstract The 2005 National Institutes of Health (NIH) Consensus Conference proposed new
criteria for diagnosing and scoring the severity of chronic graft-versus-host disease (GVHD) …

Abstract The 2006 National Institutes of Health (NIH) Consensus paper presented
recommendations by the Ancillary Therapy and Supportive Care Working Group to support …

Introduction Chronic graft-versus-host disease (cGVHD) is a serious immune-mediated
complication after allogeneic haematopoietic stem cell transplantation (HSCT), but in …

Biology-based markers to confirm or aid in the diagnosis or prognosis of chronic graft-versus-
host disease (GVHD) after allogeneic hematopoietic cell transplantation or monitor its …

In the summer of 2013, the second Chronic GVHD Consensus conference was approved,
thanks to major funding support provided by the National Cancer Institute, Center for Cancer …